refractory non-hodgkin's lymphoma Clinical Research Trials

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (3)

Phase 1 (1)
Phase 2 (1)
Unknown (1)

Interventional (3)

Hebei Senlang Biotechnology Inc., Ltd. (1)
National Cancer Institute (NCI) (1)
Sanofi (1)

No (3)

No (3)

Adult (18+) (3)
Pediatric (Under 18) (2)

I am/have/had

I am/have/hadneuroblastoma

I am/have/hadstem cell infusion

I am/have/hadblood count

I am/have/hadmyelosuppressive chemotherapy

I am/have/hadshake

I am/have/hadantibody therapy

I am/have/hadcore needle biopsy

I am/have/hadrecurrent ependymoma

I am/have/hadmetastatic disease

I am/have/hadcutaneous t-cell lymphoma

I am/have/hadhodgkin's disease

I am/have/haddiffuse large b-cell lymphoma

I am/have/hadmedulloblastoma

I am/have/hadoxygen saturation

I am/have/hadblood transfusion

I am/have/hadcns involvement

I am/have/hadbone marrow procedure

I am/have/hadrecurrent langerhans cell histiocytosis

I am/have/hadgenetic alteration

I am/have/hadrecurrent childhood rhabdomyosarcoma

added new label for I am/have/had

I am looking for

I am looking foranticancer agents

I am looking forchemotherapeutic agents

I am looking forcytokines

I am looking foranticonvulsants

I am looking forinterleukins

I am looking fortipifarnib

I am looking forradiopharmaceutical

I am looking fornitrosourea

I am looking fortumor markers

I am looking forpediatric

I am looking for131i-mibg

I am looking formelanoma

I am looking forgrowth factor

I am looking fornitrosoureas

I am looking fordexamethasone

I am looking fornervous system

I am looking forcorticosteroids

I am looking forpegfilgrastim

I am looking forantineoplastic

I am looking forantineoplastic agents

added new label for I am looking for

Advanced Filters

Found 3 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

For pediatric ages
For Seniors
Recruiting in 10s
Interventional Study
all
Hematology
Recruiting

Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

This is a study of patients with relapsed or refractory non-Hodgkin's lymphoma. To evaluate the safety and efficacy of SL1904B in patients with relapsed or refractory non-Hodgkin's lymphoma.

non-hodgkin lymphoma

hodgkin's disease

non-hodgkin's lymphoma refractory

absolute neutrophil count

refractory non-hodgkin's lymphoma

0 views
19 Feb, 2024

Multi-country trial
Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Family Medicine
Recruiting

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To characterize the …

chronic lymphocytic leukemia

cancer treatment

cancer therapy

lymphoma

cancer

0 views
19 Feb, 2024
5 locations

Phase 2
For pediatric ages
For adults
Recruiting in 10s
Interventional Study
all
Endocrinology
Recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

neuroblastoma

stem cell infusion

tipifarnib

blood count

myelosuppressive chemotherapy

0 views
19 Feb, 2024